drugset / Trial / NCT01806259

Ketorolac in Breast Cancer Surgery

NCT01806259

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Do the use of Ketorolac in one intravenous injection at the moment of the operative incision reduce the number of recurrence in patient with advanced breast cancer without inflammation signs.

Timeline

Start
2013-02
Primary completion
2015-10
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Other / unclassified 30 mg Intravenous